Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04710628
Title Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)
Acronym PECATI
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | FRA | ESP


No variant requirements are available.